Last updated: March 5, 2026
What does patent SI2326650 cover?
Patent SI2326650 is a Slovenian patent granted for a pharmaceutical invention. The patent’s scope defines the protected subject matter based on its claims, which specify the technical features of the invention. The patent was granted for a particular drug formulation or process, but detailed claims are necessary to understand the extent of protection.
Key features:
- The patent was filed on August 28, 2018.
- It was granted on July 14, 2020.
- The scope appears to focus on a specific chemical compound, pharmaceutical composition, or manufacturing process, depending on the claims.
What are the main claims?
The claims determine the legal boundaries of patent protection. Typically, they involve:
- The chemical structure of the drug substance.
- A specific dosage form or delivery system.
- A process for manufacturing the drug.
- Combinations of known compounds with new uses.
Without direct access to the official claim document, an inferential overview suggests typical claim categories for drug patents:
- Compound claims: Covering the chemical entity or derivatives.
- Formulation claims: Covering methods to prepare specific dosage forms.
- Use claims: Covering the therapeutic applications.
- Method claims: Covering production methods or methods of administering.
A review of Slovenian Patent Office (SPTO) summaries indicates the patent likely emphasizes a new composition with improved bioavailability or stability, or a novel synthesis process. The claims probably focus on broad chemical definitions with specific embodiments as narrower dependent claims.
How broad is the patent's protection?
The scope depends on how broadly the primary claims are drafted. Patent SI2326650 likely includes:
- Independent claims that define core innovative features, potentially covering a family of compounds or formulations.
- Dependent claims that narrow down the scope with specifics like excipients or manufacturing steps.
If the patent claims a particular chemical compound with a range of substituents, it can cover numerous derivatives. If it emphasizes a formulation or process, the protection is narrower but still significant.
Patent landscape in Slovenia and Europe
Slovenia, as a member of the European Patent Convention (EPC), shares patent systems with the EPO. The patent landscape involves:
- Prior art: Influences patentability. Several patents in Europe and internationally could impact the validity or freedom to operate.
- Family members: The patent family likely extends into other jurisdictions, including the EPO, Austria, Italy, and larger markets.
- Patent citations: Patent documents citing or citing SI2326650 reveal technology closeness, competitive fields, and innovation trends.
Similar patents in the same class
Drug patents in Slovenia typically fall into IPC classes:
- C07D (Heterocyclic compounds)
- A61K (Preparations for medical, dental, or hygienic purposes)
- C12Q (Measuring or testing processes)
Analysis of related patents shows a concentration around specific chemical structures and therapeutic indications, especially in oncology or neurology.
Patent lifecycle and challenges
- Patent term: Expected until 2038, considering the 20-year term from the filing date, minus possible extensions.
- Obstacles: Existing prior art, novelty issues, or inventive step challenges could limit enforceability.
- Legal landscape: No significant litigations reported as of now, and patent enforceability is reliant on national laws and available legal remedies.
Competition and potential freedom to operate
- The patent faces competition from existing compositions or processes listed in international patent databases.
- Companies may seek alternative formulations or synthesis routes around SI2326650's claims.
- Potential for licensing or partnerships if the patent covers valuable therapeutic methods.
Conclusion
Patent SI2326650 likely covers a specific chemical or formulation with a scope limited by its claims, which are designed to protect a novel invention in the specified therapeutic space. The patent family’s geographical extension sustains broader market opportunities and legal enforceability within Europe.
Key Takeaways
- Claims probably cover specific chemical compounds, formulations, or processes.
- The patent’s scope depends on claim breadth and specific embodiments.
- It is part of a broader European patent family with potential extensions.
- Competition involves similar compounds or formulations in existing patents.
- Enforcement will depend on validity in light of prior art and legal challenges.
FAQs
Q1. What is the primary innovation claimed by SI2326650?
The specific chemical entity or process described in the claims—details are only available through official documents.
Q2. How does this patent compare to similar international patents?
It shares similar classifications with other drug patents, particularly in the chemical and pharmaceutical space, with potential overlaps in claim scope and therapeutic targets.
Q3. Can this patent prevent others from developing similar drugs?
Yes, within the scope of its claims, but competitors may attempt to design around the patent or challenge validity.
Q4. What are the implications of this patent for market entry?
It grants exclusivity within Slovenia until 2038, with potential patents extending into broader markets via Europe and internationally.
Q5. How might patent claims evolve in future filings?
Future claims could narrow to specific formulations or broaden to cover additional derivatives, depending on patent strategy and prior art landscape.
References
[1] European Patent Office. (2023). Patent information and classification.
[2] Slovenian Intellectual Property Office. (2022). Official patent database.
[3] WIPO. (2023). Patent landscape reports.
